Tips & News

Latest News

Mission 2024
Genekam making ready for Nasdaq IPO 2024
Slide 1

LATEST NEWS:

BIO CEO & Investor Conference in New York (26 and 27.2.2024)

The results of the above conference are as follows: 17 meetings were confirmed. 14 meetings with investment banks and investors took place. Now we have to do the follow up these meeting with investment banks and investors to see the final results.

Slide 1

LATEST NEWS:

Genekam Biotechnology AG is developing diagnostic tests for early detection of SARS CoV-2 vaccine and post vaccination complications.

Slide 1

LATEST NEWS:

Genekam Biotechnology AG has developed a small molecule with potential to treat SARS CoV-2 vaccine complication and is going to start in vitro studies.

Slide 1

MEDICA 2024

Visit us on Medica Duesseldorf, 11.-14. November 2024

Slide 1

LSX World conference

Genekam is to attend LSX World conference 29-30 April, 2024, Business Design Center, London, UK

Slide 1

EUDAMED

A number of Genekam products are registered with EUDAMED
A step towards meeting the lastest IVDR requirements

Products

SHOWCASE

Latest Products

CONTACT US

Do You Have Any
Questions?

  • Genekam Biotechnology AG
    Duissern Str. 65a
    47058 Duisburg, Germany

  • 49 203 / 555 858 -31 / -32 / -33
    Mobil (WhatsApp): 49 (0)170 / 3503779
    Skype: genekam-biotechnology

  • anfrage@genekam.de